Gabapentin: Side Effects, Uses & Monitoring
Facts extracted from current FDA product labeling for Gabapentin. Educational only — not medical advice.
Reported adverse reactions
| Reaction | Highest frequency reported* |
|---|---|
| Dizziness | 28% |
| Somnolence | 21.4% |
| Fatigue | 11% |
| Viral infection | 10.9% |
| Fever | 10.1% |
| Nausea and/or vomiting | 8.4% |
| Peripheral edema | 8.3% |
| Nystagmus | 8.3% |
| Hostility | 7.6% |
| Tremor | 6.8% |
| Asthenia | 5.7% |
| Diarrhea | 5.7% |
| Infection | 5.1% |
| Dry mouth | 4.8% |
| Amblyopiab | 4.2% |
| Emotional lability | 4.2% |
| Rhinitis | 4.1% |
| Constipation | 3.9% |
| Nausea | 3.9% |
| Bronchitis | 3.4% |
*Highest percentage across placebo-controlled trial tables summarized in current labeling.
Labeled uses
Postherpetic Neuralgia Gabapentin tablets USP are indicated for the management of postherpetic neuralgia in adults. Epilepsy Gabapentin tablets USP are indicated as adjunctive therapy in the treatment of partial seizures with and without secondary generalization in patients over 12 years of age with epilepsy. Gabapentin tablets USP are also indicated as adjunctive therapy in the treatment of partial seizures in pediatric patients age 3 to 12 years.
Source: FDA labeling via NIH DailyMed (set 01aafb0d…). Not affiliated with FDA or NIH.
Medical disclaimer: Always consult a qualified healthcare professional about any medication.